0001171843-23-005225.txt : 20230810 0001171843-23-005225.hdr.sgml : 20230810 20230810161046 ACCESSION NUMBER: 0001171843-23-005225 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230810 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230810 DATE AS OF CHANGE: 20230810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aptose Biosciences Inc. CENTRAL INDEX KEY: 0000882361 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32001 FILM NUMBER: 231159446 BUSINESS ADDRESS: STREET 1: 251 CONSUMERS ROAD STREET 2: SUITE 1105 CITY: TORONTO STATE: A6 ZIP: M2J 4R3 BUSINESS PHONE: 647-479-9828 MAIL ADDRESS: STREET 1: 251 CONSUMERS ROAD STREET 2: SUITE 1105 CITY: TORONTO STATE: A6 ZIP: M2J 4R3 FORMER COMPANY: FORMER CONFORMED NAME: Aptose Biosciences Inc., (formerly LORUS THERAPEUTICS INC.) DATE OF NAME CHANGE: 20140905 FORMER COMPANY: FORMER CONFORMED NAME: LORUS THERAPEUTICS INC DATE OF NAME CHANGE: 19990308 FORMER COMPANY: FORMER CONFORMED NAME: IMUTEC PHARMA INC DATE OF NAME CHANGE: 19970113 8-K 1 f8k_081023.htm FORM 8-K Form 8-K
0000882361 False 0000882361 2023-08-10 2023-08-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 10, 2023

_______________________________

Aptose Biosciences Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Canada001-3200198-1136802
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

251 Consumers Road, Suite 1105

Toronto, Ontario M2J 4R3
Canada

(Address of Principal Executive Offices) (Zip Code)

(647) 479-9828

(Registrant's telephone number, including area code)

 

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Shares, no par valueAPTONasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
Item 2.02. Results of Operations and Financial Condition.

On August 10, 2023, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.
      
99.1 Press Release dated August 10, 2023
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 Aptose Biosciences Inc.
   
  
Date: August 10, 2023By: /s/ William G. Rice, Ph.D.        
  William G. Rice, Ph.D.
  Chairman, President, and Chief Executive Officer
  

 

 EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

Aptose Reports Results for the Second Quarter 2023

            ─ CRc Response Rate 50% with Tuspetinib/Venetoclax Doublet in Evaluable Patients ─

─ CRc 44% in Patients Who Failed Prior Venetoclax ─
─ CRc 43% in Patients with Wildtype FLT3 ─
─ CRc 67% in Patients with Mutated FLT3 ─

─ Data Guide to Accelerated Approval Path for TUS/VEN Doublet in Patients Who Failed Prior Venetoclax, Including FLT3 Mutated and Wildtype ─

─ Hanmi Pharmaceutical Commits Investment in Aptose Up to 19.99% Ownership or $7 Million ─

─ Conference Call and Webcast at 5:00 pm ET Today ─

SAN DIEGO and TORONTO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the three months ended June 30, 2023, and provided a corporate update.

“While still early in our APTIVATE dose expansion trial with tuspetinib in combination with venetoclax (TUS/VEN), we are encouraged by what we’re seeing in very difficult to treat AML populations,” said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer. “Of particular importance are the tolerability of the TUS/VEN doublet and the breadth of responses in deep relapsed or refractory (R/R) AML patients who failed prior therapy with venetoclax (4 of 9 evaluable with Prior-VEN), among which responses were achieved in patients with wildtype FLT3 (2 of 3 evaluable with FLT3-WT) and one of whom harbored a TP53 mutation. Given the paucity of treatment options in this subpopulation that failed prior venetoclax therapy, we're excited to build off of these positive results at future medical meetings later this year and leverage the TUS/VEN doublet data as a springboard to future triplet therapy in the front line setting.”

“We are delighted to strengthen our relationship with Hanmi Pharmaceutical, which we believe reflects their recognition of the growing value of tuspetinib as a unique treatment for AML and possibly MDS, of the significant progress that Aptose has made with tuspetinib’s clinical development, and of the experienced and thoughtful nature of our team,” said Dr. Rice. “We thank the Hanmi team, and in particular, Ms. Juhyun Lim, President of Hanmi Pharmaceutical, for her leadership and commitment to Aptose.”

Key Corporate Highlights

  • Tuspetinib APTIVATE Expansion Trial – In the APTIVATE Phase 1/2 clinical trial of tuspetinib, a once daily oral agent with a unique kinase targeting pattern being developed for the treatment of patients with R/R AML, the tuspetinib and venetoclax (TUS/VEN) doublet combination treatment arm has demonstrated early responses (composite Complete Response rate (CRc) includes any CR, CRh, CRi and CRp to date) among efficacy evaluable R/R patients who previously failed venetoclax treatment. Among fifteen (15) patients dosed with TUS/VEN as of August 1, 2023, ten (10) patients have reached an efficacy evaluable stage. Among the ten evaluable patients, five (5) patients have achieved responses (50% CRc). Nine (9) of the ten (10) evaluable patients had failed prior venetoclax treatment, with four (4) of the nine (9) achieving responses (44% CRc). Three (3) responses emerged among seven (7) patients with wildtype FLT3 (43% CRc), which accounts for approximately 70% of the AML population, yet there are few treatment options and little in development for the wildtype patient population. The TUS/VEN combination continues to be well tolerated.

    Aptose has a growing network of U.S. and international clinical sites recruiting a large spectrum of the R/R AML population, and the APTIVATE trial is focused on the rapid enrollment of patients to the TUS/VEN doublet.

  • Equity Investments in Aptose – Today, Aptose announced that it has entered into a binding term sheet with Hanmi Pharmaceutical, Inc. (“Hanmi Pharmaceutical”) of Seoul, South Korea, for an investment of up to $7 million or 19.99 percent ownership interest in Aptose, in two tranches. The investment will provide additional financing for Aptose’s lead hematology drug, tuspetinib, formerly HM43239, which was licensed from Hanmi Pharmaceutical in November 2021 and is currently in the APTIVATE international phase 1/2 expansion trial in which patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) receive tuspetinib monotherapy or in combination with venetoclax. The Company anticipates that the first tranche for $3 million will close by the end of August, subject to the satisfaction of customary closing conditions. The second tranche for up to $4 million or a maximum of 19.99 percent ownership interest will be triggered upon Aptose achieving certain manufacturing and data milestones related to tuspetinib, to be described in greater detail in definitive documentation and anticipated to be achieved by year-end.

    The investment is conditional upon the Company receiving the conditional approval of the Toronto Stock Exchange (the “TSX”) to list the Common Shares on the TSX. Listing will be subject to satisfying all of the requirements of the TSX. The investment is also subject to the requirements of the Nasdaq Capital Market.

    During the quarter, Aptose also entered into a $25 million committed equity facility with Keystone Capital that provides Aptose the right to issue and sell up to $25 million of its common shares over the course of 24 months to the investor, subject to certain conditions being met, and subject to certain limitations and conditions imposed by Nasdaq, SEC and other regulators.

  • Completed Successful Type B EOP1 Meeting with US FDA – In June, Aptose held an End of Phase 1 (EOP1) Meeting with the FDA, where all tuspetinib data was reviewed. A monotherapy recommended Phase 2 dose of 80 mg daily was selected and all tuspetinib development paths remain open, including the single arm accelerated path.

Expected Milestones

  • European School of Haematology (ESH) Meeting – Plan to present expanded tuspetinib clinical data set (October 2023)

  • 65th American Society of Hematology (ASH) Annual Meeting & Exposition – Plan to present more mature clinical data set with tuspetinib (December 2023)

  • Plan to discuss strategies for potential future monotherapy accelerated development, doublet phase 2 development, and triplet pilot development (4Q 2023)

FINANCIAL RESULTS OF OPERATIONS


Aptose Biosciences, Inc.

Statements of Operations Data

(unaudited)

($ in thousands, except per share data)
 
 Three months endedSix months ended
 June 30, June 30,
  2023202220232022
Expenses:        
Research and development$10,582 $7,341 $19,393 $14,734 
General and administrative 3,870  3,332  9,155  7,439 
Operating expenses 14,452  10,673  28,548  22,173 
Other income, net 323  108  743  127 
             
Net loss$(14,129)$(10,565)$(27,805)$(22,046)
             
Net Loss per share, Basic and diluted$(2.27)$(1.72)$(4.47)$(3.59)
Weighted average number of common shares outstanding used in computing net loss per share, basic and diluted (in thousands) 6,234  6,150  6,219  6,149 
             

Net loss for the three-month period ended June 30, 2023 increased by $3.6 million to $14.1 million, as compared to $10.6 million for the comparable period in 2022. Net loss for the six-month period ended June 30, 2023 increased by $5.7 million to $27.8 million, as compared to $22 million for the comparable period in 2022.


Aptose Biosciences, Inc.

Balance Sheet Data

(unaudited)

($ in thousands)
 
  June 30, December 31,
  2023 2022
Cash, cash equivalents and short-term investments$23,306  $46,959 
Working capital  13,287   37,235 
Total assets  26,575   51,027 
Long-term liabilities  817   1,002 
Accumulated deficit  (492,135)  (464,330)
Stockholders’ equity  13,786   37,741 
       
  • Total cash and cash equivalents and investments as of June 30, 2023, were $23.3 million, a decrease of $12.4 million as compared to March 31, 2023, and a decrease of $23.7 million as compared to December, 31, 2022. Based on current operations, the Company expects that cash on hand and available capital provide the Company with sufficient resources to fund planned Company operations including research and development through March of 2024. 

  • Common shares outstanding on August 10, 2023, were 6,519,201.

RESEARCH AND DEVELOPMENT EXPENSES

The research and development expenses for the three-month and six-month periods ended June 30, 2023, and 2022 were as follows:

  Three months ended Six months ended
  June 30, June 30,
(in thousands) 2023 2022 2023 2022
         
Program costs – Tuspetinib$8,070$2,343$12,845$3,521
Program costs – Luxeptinib 706 2,404 1,995 5,234
Program costs – APTO-253 19 188 26 279
Personnel related expenses 1,506 1,860 3,584 4,194
Stock-based compensation 271 537 924 1,483
Depreciation of equipment 10 9 19 23
Total$10,582$7,341$19,393$14,734
         

Research and development expenses increased by $3.2 million to $10.6 million for the three-month period ended June 30, 2023, as compared to $7.3 million for the comparative period in 2022. Changes to the components of our research and development expenses presented in the table above are primarily as a result of the following events:

  • Program costs for tuspetinib were $8.1 million for the three-month period ended June 30, 2023. The higher program costs for Tuspetinib in the current period represent the enrollment of patients in our APTIVATE clinical trial, our healthy volunteer trial, manufacturing activities to support clinical development, and related expenses.
  • Program costs for luxeptinib decreased by approximately $1.7 million, primarily due to lower clinical trial costs and lower manufacturing costs as a result of the current formulation requiring less API than the prior formulation.
  • Program costs for APTO-253 decreased by approximately $169 thousand, due to the Company’s decision on December 20, 2021 to discontinue further clinical development of APTO-253.
  • Personnel-related expenses decreased by $354 thousand, related to fewer employees in the current three-month period, partially offset by salary increases.
  • Stock-based compensation decreased by approximately $266 thousand in the three months ended June 30, 2023, compared to the three months ended June 30, 2022, primarily due to stock options granted with lower grant date fair values, in the current period.

Research and development expenses increased by $4.7 million to $19.4 million for the six-month period ended June 30, 2023, as compared to $14.7 million for the comparative period in 2022. Changes to the components of our research and development expenses presented in the table above are primarily as a result of the following events:

  • Program costs for tuspetinib were $12.8 million for the six-month period ended June 30, 2023, an increase of $9.3 million compared with $3.5 million in the corresponding period in 2022. The higher program costs for Tuspetinib in the current period represent the enrollment of patients in our APTIVATE clinical trial, our healthy volunteer trial, clinical study supplies, and related expenses.
  • Program costs for luxeptinib decreased by approximately $3.2 million from $5.2 million in the six months ended June 30, 2022 to $2.0 million in the current period, primarily due to lower clinical trial costs and lower manufacturing costs as a result of the current formulation requiring less API than the prior formulation.
  • Program costs for APTO-253 decreased by approximately $253 thousand, due to the Company’s decision on December 20, 2021 to discontinue further clinical development of APTO-253.
  • Personnel-related expenses decreased by $610 thousand, related to fewer employees in the current six-month period and partially offset by salary increases.
  • Stock-based compensation decreased by approximately $559 thousand in the six months ended June 30, 2023, compared to the three months ended June 30, 2022, primarily due to stock options granted with lower grant date fair values, in the current period.
 
Conference Call & Webcast:
  
Date:Thursday, August 10, 2023
Time:
5:00 PM ET
Audio Webcast Only:link
Q&A Participant Registration Link*:link (https://register.vevent.com/register/BI29f5f8f4655b45cf8b92fd8f79f69f8f) 
  

*Analysts interested in participating in the question-and-answer session will pre-register for the event from the participant registration link above to receive the dial-in numbers and a unique PIN, which are required to access the conference call. They also will have the option to take advantage of a Call Me button and the system will automatically dial out to connect to the Q&A session.

The audio webcast also can be accessed through a link on the Investor Relations section of Aptose’s website here. A replay of the webcast will be available on the Company’s website for 30 days.

The press release, the financial statements and the management’s discussion and analysis for the quarter ended June 30, 2023 will be available on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov/edgar.shtml.

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase 1/2 expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase 1 a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies. For more information, please visit www.aptose.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements regarding the expected cash runway of the Company, the investment of Hanmi into the Company, including the anticipated closing date, the structure of such investment, the ability to receive the full $7 million investment and the proposed use of proceeds, the Company’s clinical development plans, the clinical potential, anti-cancer activity, therapeutic potential and applications and safety profile of tuspetinib and luxeptinib, the APTIVATE clinical trial, patient enrollment, the luxeptinib Phase 1 a/b clinical trials and the upcoming milestones of such trials, the development and clinical potential of the G3 formulation of luxeptinib, upcoming updates regarding the clinical trials, and statements relating to the Company’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “hope” “should”, “would”, “may”, “potential” and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to obtain requisite approvals, including approval of the TSX and Nasdaq for Hanmi’s investment; our ability to complete the Hanmi investment on the terms and structure described herein or at all; our ability to meet certain milestones related to tuspetinib in order to complete the second tranche of the investment; our ability to structure the second tranche of Hanmi’s Investment to receive the full $7 million; our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market and economic conditions; inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities; unexpected manufacturing defects; the potential impact of the COVID-19 pandemic and other risks detailed from time-to-time in our ongoing current reports, quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward- looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

For further information, please contact:

Aptose Biosciences Inc.LifeSci Advisors, LLC
Susan PietropaoloDan Ferry, Managing Director
Corporate Communications & Investor Relations617-430-7576
201-923-2049Daniel@LifeSciAdvisors.com
spietropaolo@aptose.com 

 EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 10, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 10, 2023
Entity File Number 001-32001
Entity Registrant Name Aptose Biosciences Inc.
Entity Central Index Key 0000882361
Entity Tax Identification Number 98-1136802
Entity Incorporation, State or Country Code Z4
Entity Address, Address Line One 251 Consumers Road, Suite 1105
Entity Address, City or Town Toronto
Entity Address, State or Province ON
Entity Address, Postal Zip Code M2J 4R3
City Area Code 647
Local Phone Number 479-9828
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value
Trading Symbol APTO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 f8k_081023_htm.xml IDEA: XBRL DOCUMENT 0000882361 2023-08-10 2023-08-10 iso4217:USD shares iso4217:USD shares 0000882361 false 8-K 2023-08-10 Aptose Biosciences Inc. Z4 001-32001 98-1136802 251 Consumers Road, Suite 1105 Toronto ON M2J 4R3 647 479-9828 false false false false Common Shares, no par value APTO NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_081023.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_081023.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "inline": { "local": [ "f8k_081023.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_081023.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_081023.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001171843-23-005225-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-23-005225-xbrl.zip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